| Identification of six new susceptibility loci for invasive epithelial ovarian cancer KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ... Nature genetics 47 (2), 164-171, 2015 | 307 | 2015 |
| Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers EC Page, EK Bancroft, MN Brook, M Assel, MH Al Battat, S Thomas, ... European urology 76 (6), 831-842, 2019 | 209 | 2019 |
| Mind the gap: multiple events and lengthy delays before presentation with a “first seizure” AL Firkin, DJT Marco, S Saya, MR Newton, TJ O'Brien, SF Berkovic, ... Epilepsia 56 (10), 1534-1541, 2015 | 76 | 2015 |
| Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls S Saya, E Killick, S Thomas, N Taylor, EK Bancroft, J Rothwell, S Benafif, ... Familial cancer 16, 433-440, 2017 | 63 | 2017 |
| The PROFILE feasibility study: targeted screening of men with a family history of prostate cancer E Castro, C Mikropoulos, EK Bancroft, T Dadaev, C Goh, N Taylor, ... The Oncologist 21 (6), 716-722, 2016 | 37 | 2016 |
| The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening S Benafif, H Ni Raghallaigh, E McGrowder, EJ Saunders, MN Brook, ... BJU international 129 (3), 325-336, 2022 | 28 | 2022 |
| Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY) EK Bancroft, S Saya, E Brown, S Thomas, N Taylor, J Rothwell, J Pope, ... Journal of medical genetics 57 (4), 226-236, 2020 | 22 | 2020 |
| Ability of known susceptibility SNPs to predict colorectal cancer risk for persons with and without a family history MA Jenkins, AK Win, JG Dowty, RJ MacInnis, E Makalic, DF Schmidt, ... Familial Cancer 18, 389-397, 2019 | 22 | 2019 |
| The use of a risk assessment and decision support tool (CRISP) compared with usual care in general practice to increase risk-stratified colorectal cancer screening: study … JG Walker, F Macrae, I Winship, J Oberoi, S Saya, S Milton, A Bickerstaffe, ... Trials 19, 1-14, 2018 | 21 | 2018 |
| Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition C Mikropoulos, CGH Selkirk, S Saya, E Bancroft, E Vertosick, T Dadaev, ... British journal of cancer 118 (2), 266-276, 2018 | 20 | 2018 |
| A genomic test for colorectal cancer risk: is this acceptable and feasible in primary care? S Saya, JG McIntosh, IM Winship, M Clendenning, S Milton, J Oberoi, ... Public Health Genomics 23 (3-4), 110-121, 2020 | 17 | 2020 |
| Newly diagnosed seizures assessed at two established first seizure clinics: Clinic characteristics, investigations, and findings over 11 years AM McIntosh, KM Tan, TM Hakami, MR Newton, PW Carney, M Yang, ... Epilepsia Open 6 (1), 171-180, 2021 | 12 | 2021 |
| An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases: a study protocol for the SITA (Should I Take … S Milton, J McIntosh, F Macrae, P Chondros, L Trevena, M Jenkins, ... Trials 22, 1-17, 2021 | 11 | 2021 |
| The impact of a comprehensive risk prediction model for colorectal cancer on a population screening program S Saya, JD Emery, JG Dowty, JG McIntosh, IM Winship, MA Jenkins JNCI Cancer Spectrum 4 (5), pkaa062, 2020 | 11 | 2020 |
| Exploring a novel method for optimising the implementation of a colorectal cancer risk prediction tool into primary care: a qualitative study S Milton, JD Emery, J Rinaldi, J Kinder, A Bickerstaffe, S Saya, ... Implementation Science 17 (1), 31, 2022 | 10 | 2022 |
| Clinicians’ opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50–70 years: a qualitative study S Milton, J McIntosh, T Yogaparan, P Alphonse, S Saya, ... BMJ open 11 (2), e042261, 2021 | 10 | 2021 |
| Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations EK Bancroft, S Saya, EC Page, K Myhill, S Thomas, J Pope, ... BJU international 123 (2), 284-292, 2019 | 10 | 2019 |
| Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care JG McIntosh, J Minshall, S Saya, A Bickerstaffe, N Hewabandu, A Qama, ... British Journal of General Practice 69 (689), e836-e842, 2019 | 9 | 2019 |
| Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes C Loveday, A Garrett, P Law, S Hanks, E Poyastro-Pearson, JW Adlard, ... Annals of oncology 33 (12), 1318-1327, 2022 | 8 | 2022 |
| Continuing a pregnancy after diagnosis of a lethal fetal abnormality: views and perspectives of Australian health professionals and parents A Weeks, S Saya, J Hodgson Australian and New Zealand Journal of Obstetrics and Gynaecology 60 (5), 746-752, 2020 | 8 | 2020 |
